ECSP077401A - Medicamentos que contienen compuestos de carbonilo y su uso - Google Patents

Medicamentos que contienen compuestos de carbonilo y su uso

Info

Publication number
ECSP077401A
ECSP077401A EC2007007401A ECSP077401A ECSP077401A EC SP077401 A ECSP077401 A EC SP077401A EC 2007007401 A EC2007007401 A EC 2007007401A EC SP077401 A ECSP077401 A EC SP077401A EC SP077401 A ECSP077401 A EC SP077401A
Authority
EC
Ecuador
Prior art keywords
containing carbon
carbon compounds
medications containing
medications
compounds
Prior art date
Application number
EC2007007401A
Other languages
English (en)
Inventor
Dieter Dorsch
Bertram Cezanne
Werner Mederski
Christos Tsaklakid Tsaklakidis
Johannes Gleitz
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP077401A publication Critical patent/ECSP077401A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de compuestos de la fórmula I en la que D, E, G, W, X, Y, T, R1 y R2 tienen el significado indicado en la reivindicación de patente 1, para la prevención y/o la terapia de enfermedades tromboembólicas.
EC2007007401A 2004-09-22 2007-04-17 Medicamentos que contienen compuestos de carbonilo y su uso ECSP077401A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004045796A DE102004045796A1 (de) 2004-09-22 2004-09-22 Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung

Publications (1)

Publication Number Publication Date
ECSP077401A true ECSP077401A (es) 2007-05-30

Family

ID=35149637

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007401A ECSP077401A (es) 2004-09-22 2007-04-17 Medicamentos que contienen compuestos de carbonilo y su uso

Country Status (18)

Country Link
US (1) US20080003214A1 (es)
EP (1) EP1791597A2 (es)
JP (1) JP2008513387A (es)
KR (1) KR20070054210A (es)
CN (1) CN101102818A (es)
AR (1) AR050945A1 (es)
AU (1) AU2005287637A1 (es)
BR (1) BRPI0515592A (es)
CA (1) CA2581172A1 (es)
DE (1) DE102004045796A1 (es)
EC (1) ECSP077401A (es)
IL (1) IL181964A0 (es)
MX (1) MX2007003175A (es)
PE (1) PE20060527A1 (es)
RU (1) RU2007115157A (es)
TW (1) TW200612910A (es)
WO (1) WO2006032342A2 (es)
ZA (1) ZA200703272B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004047254A1 (de) * 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
MX2007010602A (es) * 2005-03-24 2008-03-04 Warner Lambert Co Formas cristalinas de un inhibidor del factor xa de pirrolidina conocido.
US7820699B2 (en) * 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
CA2653753C (en) 2006-05-16 2013-09-24 Boehringer Ingelheim International Gmbh Substituted prolinamides, production thereof and their use as medicaments
US7811549B2 (en) * 2006-07-05 2010-10-12 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
DE602007011793D1 (de) 2006-10-18 2011-02-17 Pfizer Prod Inc Biaryl-ether-harnstoffverbindungen
CA2666922A1 (en) * 2006-10-25 2008-05-02 F. Hoffmann-La Roche Ag Novel heteroaryl carboxamides
US20080227823A1 (en) * 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
WO2009004383A2 (en) * 2007-07-03 2009-01-08 Astrazeneca Ab Aza-bicyclohexane compounds useful as anticoagulants
EP2227466B1 (de) * 2007-11-30 2011-04-20 Bayer Schering Pharma Aktiengesellschaft Heteroaryl-substituierte piperidine
WO2009092516A2 (en) * 2008-01-22 2009-07-30 Adenobio N.V. Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects
DE102009014484A1 (de) * 2009-03-23 2010-09-30 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
US8673920B2 (en) * 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
DE102009022896A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
DE102009022894A1 (de) * 2009-05-27 2010-12-02 Bayer Schering Pharma Aktiengesellschaft Substituierte Piperidine
WO2012058116A1 (en) 2010-10-27 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2012058134A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
PT2661433T (pt) 2011-01-04 2017-10-24 Novartis Ag Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd)
US9062070B2 (en) 2011-08-19 2015-06-23 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9527830B2 (en) 2011-09-16 2016-12-27 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062892A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US8999991B2 (en) 2011-10-25 2015-04-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773199B1 (en) 2011-10-31 2019-04-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066717A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013090271A1 (en) 2011-12-16 2013-06-20 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
PL2794600T3 (pl) 2011-12-22 2018-06-29 Novartis Ag Pochodne 2,3-dihydro-benzo[1,4]oksazyny i powiązane związki jako inhibitory kinazy fosfoinozytydu-3 (PI3K) do leczenia np. reumatoidalnego zapalenia stawów
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
EP2867226B1 (en) 2012-06-28 2018-11-14 Novartis AG Complement pathway modulators and uses thereof
CN104640855B (zh) 2012-06-28 2017-08-29 诺华股份有限公司 补体途经调节剂及其用途
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JP6238980B2 (ja) 2012-07-12 2017-11-29 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
CA2881566A1 (en) * 2012-07-19 2014-01-23 Yohei Ikuma 1-(cycloalkyl-carbonyl)proline derivative
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
US9777002B2 (en) 2012-11-29 2017-10-03 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2934533B1 (en) 2012-12-19 2017-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014126944A2 (en) 2013-02-18 2014-08-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US9765074B2 (en) 2013-03-15 2017-09-19 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3027625B1 (en) 2013-07-31 2018-05-30 Merck Sharp & Dohme Corp. Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure
WO2015065866A1 (en) 2013-10-31 2015-05-07 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AU2014378428A1 (en) * 2014-01-14 2016-09-01 Sumitomo Dainippon Pharma Co., Ltd. Condensed 5-oxazolidinone derivative
CN104262340B (zh) * 2014-09-19 2016-08-31 济南诚汇双达化工有限公司 一种他达拉非的制备方法
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2018093695A1 (en) 2016-11-18 2018-05-24 Merck Sharp & Dohme Corp. FACTOR XIIa INHIBITORS
EP3768378A4 (en) 2018-03-22 2021-11-17 InCarda Therapeutics, Inc. INNOVATIVE METHOD OF SLOWING THE VENTRICULAR RATE
US11020384B2 (en) 2019-08-01 2021-06-01 Incarda Therapeutics, Inc. Antiarrhythmic formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US6673817B1 (en) * 1999-05-24 2004-01-06 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
DE10314702A1 (de) * 2003-03-31 2004-10-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von Telmisartan
MXPA05010444A (es) * 2003-04-03 2005-11-04 Merck Patent Gmbh Compuestos de carbonilo.
DE10315377A1 (de) * 2003-04-03 2004-10-14 Merck Patent Gmbh Carbonylverbindungen
DE10329457A1 (de) * 2003-04-03 2005-01-20 Merck Patent Gmbh Ethinylprolinderivate

Also Published As

Publication number Publication date
EP1791597A2 (de) 2007-06-06
IL181964A0 (en) 2007-07-04
DE102004045796A1 (de) 2006-03-23
RU2007115157A (ru) 2008-11-10
WO2006032342A2 (de) 2006-03-30
ZA200703272B (en) 2009-05-27
TW200612910A (en) 2006-05-01
WO2006032342A3 (de) 2007-01-11
CN101102818A (zh) 2008-01-09
JP2008513387A (ja) 2008-05-01
CA2581172A1 (en) 2006-03-30
AR050945A1 (es) 2006-12-06
US20080003214A1 (en) 2008-01-03
MX2007003175A (es) 2007-05-18
AU2005287637A1 (en) 2006-03-30
BRPI0515592A (pt) 2008-07-29
PE20060527A1 (es) 2006-07-13
KR20070054210A (ko) 2007-05-28

Similar Documents

Publication Publication Date Title
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
CY1118179T1 (el) Φαρμακευτικη συνθεση
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
CY1119536T1 (el) Συνθεση μονομερων προστατευμενου 3'-αμινο νουκλεοζιδιου
BRPI0606112A2 (pt) 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
ECSP088503A (es) COMPUESTOS de LACTAMa y MÉTODOS DE USO DE LOS MISMOS
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
PA8637301A1 (es) Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
TW200728285A (en) Diacylindazole derivatives as inhibitors of lipases and phospholipases
BRPI0410503B8 (pt) composição tópica e uso da composição
IL184051A (en) Acetylated GLP-1 compounds, containing and using pharmaceutical preparations
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
UY29796A1 (es) Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
CY1110046T1 (el) Γαβοξαδολη για τη θεραπεια της καταθλιψης και αλλων συναισθηματικων διαταραχων
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CY1112487T1 (el) Βραχειας-δρασης ηρεμιστικοι υπνωτικοι παραγοντες για αναισθησια και καταστολη
UY29790A1 (es) Sales de diariloimidazola-4-carboxamidas, composiciones que las contienen, procesos de preparación y aplicaciones
UY29741A1 (es) Sales de 1,5- diaril pirazol-3-carboxamidas, procesos de preparación, composeciones farmacéuticas que las contienen, aplicaciones y métodos de uso.
PA8531701A1 (es) Derivados de pirimidina
GT200500308A (es) Nonadepsipeptidos acilados ii
MY146444A (en) Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases